Food and The drug administration is met with OpenAI to discuss the exploit by the AI agency, according to sources with knowledge of meetings. Meetings seem to be part of a wider effort in the FDA to exploit this technology to accelerate the process of approving the drug.
“Why does a new medicine take over 10 years?” Wrote the FDA Commissioner Marty Makary on X on Wednesday. “Why are we not modernized with artificial intelligence and other things? We have just completed our first scientific grade supported by AI-Assistance for the product and this is just the beginning.”
Notes took place at the annual American Hospital Association meeting at the beginning of this week in which Makary spoke about AI potential to assist confirming recent methods of treating diabetes and some types of cancer.
Makary did not specify that Opeli was part of this initiative. But sources similar to the project say that a compact team from Opeli met with the FDA and two collaborators of the so -called government department Elon Musk many times in recent weeks. The group discussed the project called CDERGPT, which probably means Medicine assessment centerwhich regulates without a prescription and prescription drugs in the USA and study GPT. Jeremy Walsh, who was recently called the first AI FDA officer, he conducted discussions. The contract has not yet been signed.
Opeli refused to comment.
Walsh also met with Peter Bowman-Davis, a student on vacation from Yale, who is currently the director of AI in the Health and Social Welfare Department to discuss AI FDA ambitions. Politico For the first time he informed about the calling of Bowman-Davis, which is Hi Andreesen Horowitz American Dynamism Team.
After contacting -Mail on Wednesday, Robert Califf, who was the FDA commissioner in 2016-2017 and again from 2022 to January, said that the Agency’s review teams have been using AI for several years. “It will be interesting to hear the details of which parts of the review have been” supported by AI “and what it means,” he says. “There has always been a shortening of reviews and a wide consensus in which AI can help.”
Before Califf left the agency, he said that FDA is considering various ways of using AI in internal operations. “The final reviews of approval are only one part of a much larger opportunity,” he says.
To make it clear, the exploit of artificial intelligence to assist in final drug reviews would be a chance to compress only a compact part of the drug development schedule. The huge majority of drugs fail before the FDA review appears.
Rafael Rosengarten, general director of Geniałil, a precise Oncology Firma, co -founder and member of the board of the AI alliance in healthcare, claims that he is in favor of automating some tasks related to the revision process, but claims that there are guidelines on policy regarding this type of data for training AI and this type of model. “These machines are extremely expensive to learn information, but they must be trained in such a way as to learn what we want them to learn,” he says.